What's Douglas Jolly's mailing address?
Douglas's mailing address filed with the SEC is 3030 Bunker Hill St #230, San Diego, CA 92109, USA.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Tocagen
Over the last 8 years, insiders at Tocagen have traded over $0 worth of Tocagen stock and bought 339,950 units worth $1,867,749 . The most active insiders traders include Faheem Hasnain, Steven Michael Oliveira et Franklin M Berger. On average, Tocagen executives and independent directors trade stock every 99 days with the average trade being worth of $2,157,169. The most recent stock trade was executed by Steven Michael Oliveira on 14 April 2020, trading 74,301 units of TOCA stock currently worth $88,418.
What does Tocagen do?
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
What does Tocagen's logo look like?
Tocagen executives and stock owners
Tocagen executives and other stock owners filed with the SEC include:
-
Fairooz Kabbinavar,
Senior Vice President, Clinical Development -
Thomas Darcy,
Director -
Peter Rahmer,
IR Contact Officer -
Donald Williams,
Director -
Patricia Walker,
Director -
Steven Kornfeld,
Director -
Lawrence Eichenfield,
Director -
Antony Riley,
Chief Financial Officer -
Paul Wagner,
Chairman of the Board, President, Chief Executive Officer -
Steven Michael Oliveira,
10% owner -
Asha Das,
SVP & Chief Medical Officer -
Franklin M Berger,
Director -
Paul Schimmel,
Director -
Dennis N Berman,
-
Harry E Gruber,
President, Science&Innovation -
Douglas Jolly,
EVP, Research & Pharm Devel -
Martin J Duvall,
Chief Executive Officer -
Faheem Hasnain,
Director -
Mark G Foletta,
EVP & Chief Financial Officer -
David Ross Parkinson,
Director -
Lori Anne Kunkel,
Director